Asklepios BioPharmaceutical, Inc.

Asklepios BioPharmaceutical, based in the US, specializes in the development of innovative gene therapies targeting neurodegenerative diseases, leveraging advanced adeno-associated virus (AAV) technology to enhance patient outcomes. Asklepios BioPharmaceutical develops gene therapies primarily focused on adeno-associated virus (AAV) technology. Founded in 2001, it is headquartered in Durham, North Carolina, USA. The company was acquired by Bayer AG in a Trade Sale for USD 2 billion on October 26, 2020, after securing a total of USD 2 billion in funding.

Founders Alma Chanelo and R. Samulski have significant backgrounds in gene therapy development, contributing to the company’s expertise in this field. Asklepios BioPharmaceutical specializes in developing gene therapies, with a key product being AB-1005, an investigational therapy aimed at treating Parkinson’s disease. This therapy employs the transfer of glial cell line-derived neurotrophic factor (GDNF) to restore and protect dopaminergic neurons.

Currently undergoing a Phase 1b clinical trial, AB-1005 has shown promising results in stabilizing motor function in patients. The company’s customer base includes healthcare providers and research institutions, targeting markets in North America and Europe where there are significant unmet medical needs in neurodegenerative disorders. Asklepios BioPharmaceutical's revenue model is centered around collaborations with pharmaceutical companies and research institutions, focusing on advancing gene therapy products through clinical trials and commercialization. Revenue streams are expected to derive from licensing agreements, milestone payments, and partnerships aimed at research and development.

While specific pricing plans are not disclosed, revenue generation is anticipated following regulatory approvals and market entry of products like AB-1005, as the company expands its portfolio of investigational therapies. Asklepios BioPharmaceutical is focused on expanding its product pipeline, with plans for new gene therapies in development to address specific neurodegenerative conditions. The recent acquisition by Bayer AG will support these initiatives, providing access to additional resources and expertise. The company aims to expand its geographic reach into new international markets, particularly in Europe, by 2025.

The recent funding from Bayer AG will be utilized to enhance research and development activities, furthering the clinical trials of AB-1005 and other therapies, while establishing strategic partnerships to facilitate broader access and distribution.